XML 65 R56.htm IDEA: XBRL DOCUMENT v3.21.1
Loan Payable to Silicon Valley Bank (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Apr. 23, 2020
Apr. 02, 2020
Oct. 17, 2019
Mar. 31, 2021
Mar. 31, 2020
Mar. 23, 2017
Feb. 21, 2017
Debt Instrument [Line Items]              
Amortization of deferred financing costs       $ 19 $ 35    
Interest rate       3.25%      
Warrants [Member]              
Debt Instrument [Line Items]              
Warrants to purchase, shares           7,321 8,247
Warrant exercise price, per share           $ 5.46 $ 4.85
Amended Loan Agreement [Member]              
Debt Instrument [Line Items]              
Line of credit, description     Oncocyte may prepay in full the outstanding principal balance at any time, subject to a prepayment fee equal to 2.0% of the outstanding principal balance if prepaid more than one year but less than two years after October 17, 2019, or 1.0% of the outstanding principal balance if prepaid two years or more after October 17, 2019. Any amounts borrowed and repaid may not be reborrowed.        
Interest rate description     Payments of interest only on the principal balance were due monthly from the draw date through March 31, 2020, followed by 24 monthly payments of principal and interest, but the Bank has agreed to a deferral of principal payments, as discussed below. The outstanding principal balance of the loan will bear interest at a stated floating annual interest equal to the greater of (a) the prime rate or (b) 5% per annum. As of December 31, 2020, the latest published prime rate was 3.25% per annum.        
Amended Loan Agreement [Member] | Bank Warrant [Member]              
Debt Instrument [Line Items]              
Debt instrument, final payment     $ 200        
Unamortized deferred financing cost       $ 50      
Warrants to purchase, shares     98,574        
Warrant exercise price, per share     $ 1.69        
Amended Loan Agreement [Member] | Tranche One [Member]              
Debt Instrument [Line Items]              
Secured credit facility     $ 3,000        
Repayment of remaining balance     400        
Debt instrument, final payment     116        
Amended Loan Agreement [Member] | Tranche Two [Member]              
Debt Instrument [Line Items]              
Secured credit facility     2,000        
Additional equity capital     $ 20,000        
Line of credit, description     The credit line under the Amended Loan Agreement may be increased by an additional $2 million ("Tranche 2") if Oncocyte obtains at least $20 million of additional equity capital, as was the case with the original Loan Agreement, and a positive final coverage determination is received from the Centers for Medicate and Medicaid Services for DetermaRx at a specified minimum price point per test (the "Tranche 2 Milestone"), and Oncocyte is not in default under the Amended Loan Agreement.        
Interest rate     5.00%        
Amended Loan Agreement [Member] | Tranche Two [Member] | Bank Warrant [Member]              
Debt Instrument [Line Items]              
Warrant exercise price, per share     $ 0.02        
Diluted equity outstanding     $ 1,000        
Loan Deferral Agreement [Member]              
Debt Instrument [Line Items]              
Debt instrument, maturity date description   The Bank agreed to (i) extend the scheduled maturity date of the Amended Loan Agreement from March 31, 2022 to September 30, 2022, and (ii) deferred the principal payments by an additional 6 months whereby payments of interest only on the Bank loan principal balance will be due monthly from May 1, 2020 through October 1, 2020, followed by 23 monthly payments of principal and interest beginning on November 1, 2020, all provided at no additional fees to Oncocyte.          
Loan and Security Agreement [Member]              
Debt Instrument [Line Items]              
Amount borrowed             $ 2,000
Periodic payment term       Payments of interest only on the principal balance were due monthly from the loan funding date, March 23, 2017, through October 31, 2017, and, beginning on November 1, 2017      
Periodic payments of principal and interest       $ 67      
Debt instrument, maturity date       Apr. 01, 2020      
Amortization of deferred financing costs       $ 116      
Prepayment fee if prepaid two years or more       1.00%      
PPP [Member]              
Debt Instrument [Line Items]              
Amount borrowed $ 1,140,930            
Debt instrument, maturity date Apr. 23, 2022            
Debt instrument, interest rate 1.00%